175 related articles for article (PubMed ID: 30149234)
1. Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women.
Weiner CM; Mathewos A; Addissie A; Ayele W; Aynalem A; Wondemagegnehu T; Wienke A; Jemal A; Zerche P; Thomssen C; Seidler A; Kantelhardt EJ
Breast; 2018 Dec; 42():23-30. PubMed ID: 30149234
[TBL] [Abstract][Full Text] [Related]
2. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
5. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
Malmgren J; Hurlbert M; Atwood M; Kaplan HG
Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
[TBL] [Abstract][Full Text] [Related]
6. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
Seltzer S; Corrigan M; O'Reilly S
Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
[TBL] [Abstract][Full Text] [Related]
7. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
8. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
9. Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis.
Tjokrowidjaja A; Lee CK; Houssami N; Lord S
Intern Med J; 2014 Aug; 44(8):764-70. PubMed ID: 24863750
[TBL] [Abstract][Full Text] [Related]
10. Survival of breast cancer patients in rural Ethiopia.
Eber-Schulz P; Tariku W; Reibold C; Addissie A; Wickenhauser C; Fathke C; Hauptmann S; Jemal A; Thomssen C; Kantelhardt EJ
Breast Cancer Res Treat; 2018 Jul; 170(1):111-118. PubMed ID: 29479644
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer survival in Ethiopia: a cohort study of 1,070 women.
Kantelhardt EJ; Zerche P; Mathewos A; Trocchi P; Addissie A; Aynalem A; Wondemagegnehu T; Ersumo T; Reeler A; Yonas B; Tinsae M; Gemechu T; Jemal A; Thomssen C; Stang A; Bogale S
Int J Cancer; 2014 Aug; 135(3):702-9. PubMed ID: 24375396
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Survival of Patients with Malignant Ovarian Tumors in Addis Ababa, Ethiopia.
Piszczan S; Desalegn D; Petros H; Gurmu M; Kroeber ES; Addissie A; Mikolajczyk R; Ghebre RG; Mathewos A; Thomssen C; Jemal A; Kantelhardt EJ
Oncologist; 2019 Jun; 24(6):e303-e311. PubMed ID: 31023861
[TBL] [Abstract][Full Text] [Related]
13. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer.
Murthy P; Kidwell KM; Schott AF; Merajver SD; Griggs JJ; Smerage JD; Van Poznak CH; Wicha MS; Hayes DF; Henry NL
Breast Cancer Res Treat; 2016 Feb; 155(3):589-95. PubMed ID: 26875184
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
[TBL] [Abstract][Full Text] [Related]
15. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
16. Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.
Galli G; Tessari A; Porcu L; Bregni G; Paolini B; Carcangiu ML; Gennaro M; De Santis MC; Lozza L; de Braud F; Di Cosimo S
Breast Cancer; 2017 Jul; 24(4):635-641. PubMed ID: 28058615
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
[TBL] [Abstract][Full Text] [Related]
18. Use and results of systemic treatments for de novo and recurrent metastatic breast cancer: a population-based cohort study.
Lao C; Kuper-Hommel M; Campbell I; Elwood M; Lawrenson R
N Z Med J; 2021 Nov; 134(1545):47-59. PubMed ID: 34788271
[TBL] [Abstract][Full Text] [Related]
19. Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis.
Lord SJ; Marinovich ML; Patterson JA; Wilcken N; Kiely BE; Gebski V; Crossing S; Roder DM; Gattellari M; Houssami N
Med J Aust; 2012 Jun; 196(11):688-92. PubMed ID: 22708766
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for survival in metastatic breast cancer by hormone receptor status.
Kwast AB; Voogd AC; Menke-Pluijmers MB; Linn SC; Sonke GS; Kiemeney LA; Siesling S
Breast Cancer Res Treat; 2014 Jun; 145(2):503-11. PubMed ID: 24771049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]